S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Completed · Phase 3 · NCT01809691
Conditions: Prostate Cancer
At a glance
- Research payments reported, 2025
- $7,085
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,313
About the trial
- Sponsor
- SWOG Cancer Research Network (with Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI))
- Tested
- TAK-700 (drug), Bicalutamide (drug)
- Dates
- Started 2013-03-08; completion 2025-09-09
- Results posted
- Yes
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
From ClinicalTrials.gov, last updated 2025-12-31. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Menarini Silicon Biosystems, Inc. reported $7,085 in research payments for this study in 2025 (1 payments).
Products named: Cellsearch
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Usc Norris Cancer Hospital $7,085
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.